Aptar Announces Exclusive Negotiations Regarding a Potential Acquisition of Voluntis to Expand in Digital Therapeutics
AptarGroup, Inc. announced that it has entered into exclusive negotiations with respect to a potential acquisition of all outstanding shares of Voluntis (ENXTPA: ALVTX), a pioneer in digital therapeutics. This acquisition would complement Aptar’s existing digital health portfolio of connected devices by adding digital therapeutic solutions and broadening its digital health services across multiple chronic conditions and diseases. Digital therapeutics (DTx) help patients and caregivers treat, manage, or prevent a disorder or disease through evidence-based interventions that are driven by high quality software solutions. Supported by the trend toward personalized healthcare, DTx are used independently or in connection with medications, devices or other therapies to optimize patient care and health outcomes. By acquiring Voluntis, Aptar would have immediate access to an established proprietary platform and algorithms that would drive future digital solutions provided to pharmaceutical and biotech customers as well as other healthcare stakeholders including payers and providers.